Plasmablastic transformation of plasma cell myeloma with heterotropic expression of CD3 and CD4: a case report.
We describe a case of plasmablastic transformation having a pan T-cell phenotype with CD3 and CD4 positivity, in an immunocompetent elderly lady diagnosed with PCM. This 60-year-old lady presented with worsening backache and a 2-cm skin nodule in the left cervical region, while she was on treatment with vincristine, cyclophosphamide, dexamethasone (VCD), and bortezomib. On biopsy, the skin nodule showed an infiltrating lymphoid tumor composed of immunoblastic cells with brisk mitosis and apoptosis. On Immunohistochemistry (IHC), lymphoid cells revealed plasma cell markers CD38, CD138, CD56, and MUM1. Pan-T-cell markers CD3...
Source: Clinical Lymphoma and Myeloma - June 30, 2016 Category: Cancer & Oncology Authors: Mishra P, Kakri S, Gujral S Tags: Acta Clin Belg Source Type: research

Diagnosis of chronic lymphoproliferative disorders by flow cytometry using four-color combinations for immunophenotyping: A proposal of the Brazilian Group of Flow Cytometry (GBCFLUX).
CONCLUSION: The 4-color panels presented to aid in the diagnosis of lymphoproliferative neoplasms by GBCFLUX aim to provide clinical laboratories with a systematic, step-wise, cost-effective and reproducible approach to obtain an accurate immunophenotypic diagnosis of the most frequent of these disorders. This article is protected by copyright. All rights reserved. PMID: 27362793 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 30, 2016 Category: Cancer & Oncology Authors: Sales MM, Ferreira S, Ikoma M, Sandes AF, Beltrame MP, Bacal NS, Silva M, Malvezzi M, Lorand-Metze I, Orfao A, Yamamoto M, GBCFLUX Tags: Cytometry B Clin Cytom Source Type: research

Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88 L265P Mutations.
CONCLUSIONS: Non-IgM LPLs are a clinically and pathologically heterogeneous group and often harbor MYD88 L265P mutation, albeit at a lower rate than classic WM. MYD88 status does not correlate with any specific pathologic or clinical manifestations. PMID: 27329639 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 21, 2016 Category: Cancer & Oncology Authors: King RL, Gonsalves WI, Ansell SM, Greipp PT, Frederick LA, Viswanatha DS, He R, Kyle RA, Gertz MA, Kapoor P, Morice WG, Howard MT Tags: Am J Clin Pathol Source Type: research

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.
CONCLUSION: Nivolumab was well tolerated and exhibited antitumor activity in extensively pretreated patients with relapsed or refractory B- and T-cell lymphomas. Additional studies of nivolumab in these diseases are ongoing. PMID: 27269947 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 6, 2016 Category: Cancer & Oncology Authors: Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, Millenson MM, Cohen AD, Schuster SJ, Lebovic D, Dhodapkar M, Avigan D, Chapuy B, Ligon AH, Freeman GJ, Rodig SJ, Cattry D, Zhu L, Grosso JF, Bradley Garelik MB, Shipp MA, Borrello I, Timm Tags: J Clin Oncol Source Type: research

Clinical responses with T lymphocytes targeting malignancy-associated κ light chains.
CONCLUSION: κ.CART infusion is feasible and safe and can lead to complete clinical responses. TRIAL REGISTRATION: ClinicalTrials.gov NCT00881920. FUNDING: National Cancer Institute (NCI) grants 3P50CA126752 and 5P30CA125123 and Leukemia and Lymphoma Society (LLS) Specialized Centers of Research (SCOR) grant 7018. PMID: 27270177 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 6, 2016 Category: Cancer & Oncology Authors: Ramos CA, Savoldo B, Torrano V, Ballard B, Zhang H, Dakhova O, Liu E, Carrum G, Kamble RT, Gee AP, Mei Z, Wu MF, Liu H, Grilley B, Rooney CM, Brenner MK, Heslop HE, Dotti G Tags: J Clin Invest Source Type: research

Next Generation Sequencing of Chinese Stage IV Lung Cancer Patients Reveals an Association between EGFR Mutation Status and Survival Outcome.
In conclusion, tumors from stage IV NSCLC patients harbor characteristic gene alterations, of which EGFR L858R in particular appears to be a poor prognostic factor for overall survival. PMID: 27221040 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 25, 2016 Category: Cancer & Oncology Authors: Li F, Du X, Zhang H, Ju T, Chen C, Qu Q, Zhang X, Qi L, Lizée G Tags: Clin Genet Source Type: research

Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC).
CONCLUSION: In this HHMC-referred hematologic malignancy cohort, HCS was confirmed in 12 patients (18%). HCS identification provides insight for improved and individualized treatment, as well as screening/surveillance opportunities for family members. The HHMC has facilitated HCS diagnosis; with increased clinical awareness of hematologic malignancy predisposition syndromes, more patients who may benefit from evaluation can be identified. Mutation panels intended for prognostication may provide increased clinical suspicion for germ-line testing. PMID: 27210295 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 27, 2016 Category: Cancer & Oncology Authors: DiNardo CD, Bannon SA, Routbort M, Franklin A, Mork M, Armanios M, Mace EM, Orange JS, Jeff-Eke M, Churpek JE, Takahashi K, Jorgensen JL, Garcia-Manero G, Kornblau S, Bertuch A, Cheung H, Bhalla K, Futreal A, Godley LA, Patel KP Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Risk factors for malignancy in systemic sclerosis patients.
aradağ O, Kasifoglu N, Arslantas D, Sahin F, Keser G, Yavuz S, Birlik M, Onat AM Abstract Systemic sclerosis (SSc) is an autoimmune connective tissue disease with multisystem involvement. An increased incidence of cancer in SSc patients compared with the general population has been reported in several reports. Our aims in this study were to determine the most common malignancies and to investigate the possible risk factors for the development of malignancy in patients with SSc. Three hundred forty SSc patients from 13 centers were included to the study. Data of the patients were obtained by evaluating their medic...
Source: Clinical Lymphoma and Myeloma - April 27, 2016 Category: Cancer & Oncology Authors: Kaşifoğlu T, Yaşar Bilge Ş, Yıldız F, Özen G, Pehlivan Y, Yılmaz N, Tarhan F, Yılmaz S, Küçük A, Emmungil H, Koca SS, Çınar M, Direskeneli H, Erken E, Can G, Özmen M, Gönüllü E, Kisacik B, Aksu K, Karadağ O, Kasifoglu N, Arslantas D, Sa Tags: Clin Rheumatol Source Type: research

Laboratory testing in monoclonal gammopathy of renal significance (MGRS).
Abstract Recently, monoclonal gammopathy of renal significance (MGRS) reclassified all monoclonal (M) gammopathies that are associated with the development of a kidney disease but do not meet the definition of symptomatic multiple myeloma (MM) or malignant lymphoma. The purpose was to distinguish the M gammopathy as the nephrotoxic agent independent from the clonal mass. The diagnosis of MGRS obviously depends on the detection of the M-protein. More importantly, the success of treatment is correlated with the reduction of the M-protein. Therefore, familiarity with the M-protein tests is a must. Protein electrophor...
Source: Clinical Lymphoma and Myeloma - April 23, 2016 Category: Cancer & Oncology Authors: Leung N, Barnidge DR, Hutchison CA Tags: Clin Chem Lab Med Source Type: research

Treatment of Osteonecrosis in Children and Adolescents With Acute Lymphoblastic Leukemia.
CONCLUSIONS: No standard of care exists for treatment of ALL-associated ON. While considerable practice variation exists, surgical intervention appears relatively safe. PMID: 27021949 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 31, 2016 Category: Cancer & Oncology Authors: Heneghan MB, Rheingold SR, Li Y, Seif AE, Huang YS, McLeod L, Wells L, Fisher BT, Aplenc R Tags: Clin Lymphoma Myeloma Leuk Source Type: research

A novel hematopoietic progenitor cell mobilization regimen, utilizing bortezomib and filgrastim, for patients undergoing autologous transplant.
Abstract Adequate hematopoietic progenitor cell (HPC) collection is critical for patients undergoing autologous HPC transplant (AHPCT). Historically, 15 - 30% of patients failed HPC mobilization with granulocyte-colony stimulating factor (G-CSF) alone. Bortezomib, a proteasome inhibitor, has been shown to down regulate very late antigen-4 (VLA-4), an adhesion molecule expressed on HPCs. In this pilot study, bortezomib was administered on days -11 and -8 at a dose of 1.3 mg/m(2) intravenously (IV) or subcutaneously (SQ), followed by G-CSF 10 mcg/kg SQ, on days -4 to -1 prior to HPC collection (Day 1)....
Source: Clinical Lymphoma and Myeloma - March 4, 2016 Category: Cancer & Oncology Authors: Abhyankar S, Lubanski P, DeJarnette S, Merkel D, Bunch J, Daniels K, Aljitawi O, Lin T, Ganguly S, McGuirk J Tags: J Clin Apher Source Type: research

Improved Survival of Calreticulin-Mutated Patients Compared With Janus Kinase 2 in Primary Myelofibrosis: A Meta-Analysis.
CONCLUSION: The results of the present meta-analysis have confirmed the role of the CALR mutation in the diagnosis of, and as a prognostic tool for, PMF. Our results suggest that patients with the CALR mutation will have better overall survival than patients with the JAK2 mutation in a non-Asian population. PMID: 26935576 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 6, 2016 Category: Cancer & Oncology Authors: Kourie HR, Ameye L, Paesmans M, Bron D Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Daily Practice: A Multicenter Experience.
CONCLUSIONS: Current state-of-the art management of Ph(+) ALL in real-life seems to be incorporation of TKIs to chemotherapy regimens and proceeding to allo-HCT, whenever possible. PMID: 26927932 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 4, 2016 Category: Cancer & Oncology Authors: Tekgündüz E, Göker H, Kaynar L, Sarı İ, Pala Ç, Doğu MH, Öztürk E, Turgut B, Korkmaz S, Tetik A, Büyükaşık Y, Hacıoğlu SK, Bozdağ SC, Özdemir E, Altuntaş F Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Risk-Adapted Approach to HLA-Matched Sibling Hematopoietic Cell Allografting: Impact of Adjusting Conditioning Intensity and Integrating Post-Transplant Therapeutic Interventions.
CONCLUSION: This risk-adapted combined approach of selecting conditioning intensity and integrating post-transplant therapies results in lower non-relapse-mortality and encouraging improvement in survival. Our findings warrant confirmation in a large prospective multicenter trial. PMID: 26923326 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 4, 2016 Category: Cancer & Oncology Authors: El Cheikh J, Otrock ZK, Qannus AA, Kharfan-Dabaja MA, Bazarbachi A Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Management of Carfilzomib-Associated Cardiac Adverse Events.
This article discusses the cardiac-related adverse events that have been reported in clinical studies of carfilzomib and presents a single institution perspective on the prevention and management of cardiac adverse events following treatment with this agent. PMID: 26907720 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 4, 2016 Category: Cancer & Oncology Authors: Mikhael J Tags: Clin Lymphoma Myeloma Leuk Source Type: research

CHOP Chemotherapy Followed by Tositumomab and Iodine-131 Tositumomab for Previously Untreated Diffuse Large B-cell Lymphoma.
Abstract The efficacy and safety of tositumomab/iodine-131 tositumomab (TST/I-131 TST) were evaluated in diffuse large B-cell lymphoma patients who responded to first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Fifteen patients (median age, 52 years) received dosimetric and therapeutic doses of TST/I-131 TST. The most common Grade 3/4 hematologic adverse events were decreased absolute neutrophil count (47%), white blood cell count (40%), platelet count (27%), and hemoglobin (20%). The complete response (CR) rate increased from 60% post-CHOP to 80% post TST / I-131 TST. With a median fol...
Source: Clinical Lymphoma and Myeloma - January 4, 2016 Category: Cancer & Oncology Authors: Leonard JP, Gregory SA, Smith H, Horner TJ, Williams VC, Giampietro P, Lin TS Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Lymphoproliferative Disease and Hepatitis B Reactivation: Challenges in the Era of Rapidly Evolving Targeted Therapy.
Abstract Reactivation of hepatitis B virus (HBV) is a known complication that occurs in patients receiving chemotherapy especially for malignant lymphoma. The increased risk in lymphoma patients parallels the potency of the immunosuppressive treatment regimens that are provided. B-cell-depleting therapy such as anti-CD20 monoclonal antibodies, especially when combined with conventional chemotherapy, significantly increases the risk of HBV reactivation, even in patients with resolved HBV infection. The first reports of HBV reactivation with anti-CD20 therapy emerged only 4 years after its US Food and Drug Administr...
Source: Clinical Lymphoma and Myeloma - January 1, 2016 Category: Cancer & Oncology Authors: Phipps C, Chen Y, Tan D Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Bing Neel Syndrome in a Previously Untreated Patient With Waldenström's Macroglobulinemia: Contribution of MYD88 L265P Mutation on Cerebrospinal Fluid.
Bing Neel Syndrome in a Previously Untreated Patient With Waldenström's Macroglobulinemia: Contribution of MYD88 L265P Mutation on Cerebrospinal Fluid. Clin Lymphoma Myeloma Leuk. 2016 Jan;16(1):e7-9 Authors: Frustaci AM, Rusconi C, Picardi P, Veronese S, Montillo M, Cairoli R, Tedeschi A PMID: 26705679 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - January 1, 2016 Category: Cancer & Oncology Authors: Frustaci AM, Rusconi C, Picardi P, Veronese S, Montillo M, Cairoli R, Tedeschi A Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Recurrent Subepidermal Blistering Dermatosis Heralding Disease Relapse in IgA Kappa Multiple Myeloma: Report of a Case and a Review of the Literature.
PMID: 26708980 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - January 1, 2016 Category: Cancer & Oncology Authors: Leatham HW, Novoa R, Liedtke M, Kwong BY Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study.
CONCLUSION: With monitoring and prophylaxis, alemtuzumab 60 mg combined with CHOP showed activity in CD52(+) PTL and achieved the highest drug levels. PMID: 26711181 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - January 1, 2016 Category: Cancer & Oncology Authors: Buckstein R, Fraser G, Cheung M, Kukreti V, Kuruvilla J, Imrie K, Piliotis E, Pond G, Windsor J, Ghorab Z, Shuoprasad K, Turner R, Meyer RM, Pritchard K, Walker S, Levine M, Crump M Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Clinicopathologic Effect of DNMT3A Mutation in Adult T-Cell Acute Lymphoblastic Leukemia.
CONCLUSION: DNMT3A is frequently mutated in T-ALL and is associated with distinct clinicopathologic entities and a poor prognosis. These findings could help in risk stratification and treatment decisions for patients with T-ALL. PMID: 26711182 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - January 1, 2016 Category: Cancer & Oncology Authors: Aref S, El Menshawy N, El-Ghonemy MS, Zeid TA, El-Baiomy MA Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Hypercalcemia of malignancy and new treatment options.
Abstract Hypercalcemia of malignancy affects up to one in five cancer patients during the course of their disease. It is associated with both liquid malignancies, commonly multiple myeloma, leukemia, and non-Hodgkins lymphoma and solid cancers, particularly breast and renal carcinomas as well as squamous cell carcinomas of any organ. The clinical manifestations of hypercalcemia are generally constitutional in nature and not specific to the inciting malignancy. Such physical manifestations can range from malaise to lethargy and confusion. Constipation and anorexia are common. Acute kidney injury is likely the most ...
Source: Clinical Lymphoma and Myeloma - December 20, 2015 Category: Cancer & Oncology Authors: Sternlicht H, Glezerman IG Tags: Ther Clin Risk Manag Source Type: research

Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma.
Abstract Alterations in chromatin modifications, such as histone methylation, have been suggested as mediating chemotherapy resistance in several cancer types; therefore, elucidation of the epigenetic mechanisms that underlie drug resistance may greatly contribute to the advancement of cancer therapies. In the present study, we identified histone H3-lysine 27 (H3K27) as a critical residue for epigenetic modification in multiple myeloma. We determined that abrogation of drug-induced H3K27 hypermethylation is associated with cell adhesion-mediated drug resistance (CAM-DR), which is the most important form of drug re...
Source: Clinical Lymphoma and Myeloma - November 4, 2015 Category: Cancer & Oncology Authors: Kikuchi J, Koyama D, Wada T, Izumi T, Hofgaard PO, Bogen B, Furukawa Y Tags: J Clin Invest Source Type: research

Outcomes of Treatment in Slovene Follicular Lymphoma Patients.
n;ek Novaković B Abstract BACKGROUND: The outcome of follicular lymphoma (FL) patients has dramatically improved over the last 2 decades by introduction of rituximab in combination chemotherapy and into maintenance setting. We retrospectively analyzed the treatment outcomes in Slovene FL patients in the era of rituximab and compared them to the results reported by pivotal clinical studies. PATIENTS AND METHODS: Two hundred seventy-eight patients with FL treated in Slovenia between 2000 and 2010 with a median follow-up of 5.7 years were included in our retrospective analysis. One hundred ninety-three (69%) re...
Source: Clinical Lymphoma and Myeloma - October 1, 2015 Category: Cancer & Oncology Authors: Južnič Šetina T, Borštnar S, Jezeršek Novaković B Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Circulating Levels of Urokinase-Type Plasminogen Activator Receptor and D-Dimer in Patients With Hematological Malignancies.
The objective of this study was to identify in patients with hematological neoplasia, the serum levels of uPAR and D-D, and to determine their effects on outcome. PATIENTS AND METHODS: A cross-sectional study was performed. Clinical and demographic data were obtained from the clinical chart. Determination of uPAR in serum (pg/L) was performed using an enzyme-linked immunosorbent assay, and D-D (μg/dL) using nephelometry. RESULTS: We included 42 patients (35 with lymphomas). Statistically significant differences were found in D-D (P 
Source: Clinical Lymphoma and Myeloma - October 1, 2015 Category: Cancer & Oncology Authors: Rubio-Jurado B, Tello-González A, Bustamante-Chávez L, de la Peña A, Riebeling-Navarro C, Nava-Zavala AH Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Plerixafor is cost-effective compared to conventional chemotherapy for first-line haematopoietic stem cell mobilization: Data from the PHANTASTIC trial.
Abstract Plerixafor is an effective haematopoietic stem cell mobilising agent in candidates for autologous transplantation, including patients with myeloma and lymphoma. Here we compare 98 plerixafor recipients in the PHANTASTIC trial with 151 historic controls mobilised by conventional chemotherapy (each with granulocyte colony-stimulating factor, G-CSF). Seventy (71.4%) plerixafor-mobilised patients achieved the composite primary endpoint of ≥4 × 10(6) CD34+ cells kg(-1) in ≤2 aphereses and no clinically significant neutropenia, compared to 48 (31.8%) historic controls (P 
Source: Clinical Lymphoma and Myeloma - September 29, 2015 Category: Cancer & Oncology Authors: Martin AP, Richards S, Haycox A, Houten R, McLeod C, Braithwaite B, Clark JO, Bell J, Clark RE Tags: J Clin Apher Source Type: research

Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma.
CONCLUSION: GM-CSF-based chemoimmunotherapy was well-tolerated and resulted in a high response rate and warrants evaluation in larger studies. PMID: 26297176 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 27, 2015 Category: Cancer & Oncology Authors: Cohen JB, Bucur S, Winton EF, Sinha R, Heffner LT, King N, Lonial S, Langston AA, Waller EK, Hutchison-Rzepka A, Colbert A, Lechowicz MJ, Flowers CR Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Membranous nephropathy in autologous hematopoietic stem cell transplant: autologous graft-versus-host disease or autoimmunity induction?
Abstract With the increasing utility of hematopoietic stem cell transplantation (SCT) as a treatment for cancer and noncancerous disorders, more challenges and complications associated with SCT have emerged. Renal injury immediately after transplant is common and well understood, but long-term renal injury is becoming more evident. Chronic graft-versus-host disease (GVHD) is a known long-term complication of SCT, and membranous nephropathy (MN) is emerging as the most common cause of SCT-associated glomerular pathology. In this case report, we present a patient who developed features of anti-PLA2R antibody-negativ...
Source: Clinical Lymphoma and Myeloma - August 1, 2015 Category: Cancer & Oncology Authors: Abudayyeh A, Truong LD, Beck LH, Weber DM, Rezvani K, Abdelrahim M Tags: Clin Kidney J Source Type: research

Systematic review of the relationship between artificial sweetener consumption and cancer in humans: analysis of 599,741 participants.
Abstract BACKGROUND: The effect of artificial sweetener consumption on cancer risk has been debated in animal models for over four decades. To further investigate this relationship, this study aims to synthesise results from several of the most recent studies in humans. METHODS: An online literature search was performed in MEDLINE from 2003 to 2014 using Ovid, PubMed, Web of Science, and Scopus using keywords 'artificial', 'sweetener' and 'cancer'. Ninety-two results were then manually assessed for eligibility. Studies were included if the relationship between artificial sweeteners and cancer was their centra...
Source: Clinical Lymphoma and Myeloma - July 23, 2015 Category: Cancer & Oncology Authors: Mishra A, Ahmed K, Froghi S, Dasgupta P Tags: Int J Clin Pract Source Type: research

Utility of CD54, CD229 and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases.
CONCLUSIONS: From the three markers evaluated, CD229 may be considered as the most reliable marker to replace CD38 or CD138 for the identification of PCs in patients undergoing anti-CD38 or anti-CD138 therapy, until a better alternative is available. This article is protected by copyright. All rights reserved. PMID: 26130131 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 30, 2015 Category: Cancer & Oncology Authors: Pojero F, Flores-Montero J, Sanoja L, Pérez JJ, Puig N, Paiva B, Bottcher S, van Dongen JJ, Orfao A, EuroFlowgroup Tags: Cytometry B Clin Cytom Source Type: research

Adiponectin as a biomarker linking obesity and adiposopathy to hematologic malignancies.
Abstract Higher body mass index and adiposopathy have been associated with increased risk of hematologic malignancies such as leukemia, multiple myeloma, myeloproliferative disorders, Hodgkin's and non-Hodgkin's lymphoma, and myelodysplastic syndromes. Adiponectin is a multimeric protein of the white adipose tissue presenting anti-inflammatory, insulin-sensitizing, anti-atherogenic, cardioprotective, and anti-neoplastic properties. Its anti-neoplastic actions are manifested via two mechanisms: (i) direct action on tumor cells by enhancing receptor-mediated signaling pathways and (ii) indirect action by regulating ...
Source: Clinical Lymphoma and Myeloma - June 9, 2015 Category: Cancer & Oncology Authors: Dalamaga M, Christodoulatos GS Tags: Horm Mol Biol Clin Investig Source Type: research

Bortezomib-associated demyelinating neuropathy-clinical and pathologic features.
CONCLUSIONS: Although most toxic neuropathies are symmetrical axonal neuropathies, bortezomib is part of a small list of agents that may cause a demyelinating polyneuropathy and axonal degeneration. These findings have been confirmed by nerve biopsy. PMID: 25996966 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 24, 2015 Category: Cancer & Oncology Authors: Thawani SP, Tanji K, De Sousa EA, Weimer LH, Brannagan TH Tags: J Clin Neuromuscul Dis Source Type: research

Novel Treatments for T-Cell Lymphoma.
Abstract T-cell lymphomas are a biologically and clinically diverse collection of diseases that collectively account for 10% to 15% of non-Hodgkin lymphomas. Unlike B-cell lymphomas, the response of T-cell lymphomas to standard anthracycline-containing chemotherapy regimens is suboptimal and the prognosis of patients is accordingly poor. To address these shortcomings, there has been a proliferation in biologic agents with novel mechanisms of action that target surface antigens, signaling pathways, or cellular processes. Given the large number of candidate molecules showing preclinical promise and the rarity of the...
Source: Clinical Lymphoma and Myeloma - May 21, 2015 Category: Cancer & Oncology Authors: Cheah CY, Oki Y, Fanale MA Tags: Am Soc Clin Oncol Educ Book Source Type: research

Development of second primary malignancy in patients with non-Hodgkin lymphoma: a nationwide population-based study.
Abstract BACKGROUND: With the improved survival of non-Hodgkin lymphoma (NHL) patients, development of second primary malignancy (SPM) has become an increasingly important issue in these long-term survivors. METHODS: We conducted a retrospective study to analyze NHL patients diagnosed between January 1997 and December 2010 in Taiwan. Standardized incidence ratios (SIRs) were applied to compare the risk of SPMs in NHL patients and the general population. Multivariate analysis was performed to determine the independent predictors of SPM. RESULT: NHL patients have a significantly greater risk of developing ...
Source: Clinical Lymphoma and Myeloma - May 14, 2015 Category: Cancer & Oncology Authors: Chien SH, Liu CJ, Hong YC, Teng CJ, Hu YW, Ku FC, Yeh CM, Chiou TJ, Gau JP, Tzeng CH Tags: J Cancer Res Clin Oncol Source Type: research

Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah's Witnesses.
CONCLUSION: ASCT can safely be performed without transfusion support. A platelet transfusion trigger of ≤ 5 × 10(3)/μL may be appropriate in select patients. Pharmacotherapy and cardiac monitoring are effective in the management of cardiac complications. PMID: 25870085 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 13, 2015 Category: Cancer & Oncology Authors: Ford PA, Grant SJ, Mick R, Keck G Tags: J Clin Oncol Source Type: research

The t(11;14)(q13;q32) Translocation as a Poor Prognostic Parameter for Autologous Stem Cell Transplantation in Myeloma Patients With Extramedullary Plasmacytoma.
Abstract INTRODUCTION: Fluorescence in-situ hybridization (FISH)-detected abnormalities, including del(17p), del(13q), and t(4;14), have been associated with inferior prognosis. However, there are few data about the prognostic significance of cytogenetic abnormalities for autologous stem cell transplantation (ASCT) in multiple myeloma (MM) patients with extramedullary plasmacytoma (EMP). PATIENTS AND METHODS: Between April 2004 and December 2012, 290 MM patients underwent ASCT at 3 centers. FISH data for bone marrow samples obtained at diagnosis were available for 58 patients who had EMP at diagnosis or durin...
Source: Clinical Lymphoma and Myeloma - April 1, 2015 Category: Cancer & Oncology Authors: Shin HJ, Kim K, Lee JJ, Song MK, Lee EY, Park SH, Kim SH, Jang MA, Kim SJ, Chung JS Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Analysis of Prognostic Significance of Merkel Cell Polyomavirus in Chronic Lymphocytic Leukemia.
CONCLUSION: This study provides the first analysis of the prognostic role of MCPyV in CLL. MCPyV occurrence seems to be a relatively rare event during the course of CLL. MCPyV is also unlikely to influence the outcome of CLL patients. PMID: 25758600 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 11, 2015 Category: Cancer & Oncology Authors: Trizuljak J, Srovnal J, Plevová K, Brychtová Y, Semerád L, Bakešová D, Létalová E, Benedíková A, Mayer J, Hajdúch M, Pospíšilová Š, Doubek M Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Features of Extramedullary Disease of Multiple Myeloma: High Frequency of P53 Deletion and Poor Survival: A Retrospective Single-Center Study of 834 Cases.
Abstract BACKGROUND: Multiple myeloma (MM) is a heterogeneous disease in which most patients have myeloma restricted to the bone marrow, and some patients develop extramedullary disease (EMD) at the time of diagnosis or during follow-up, and show different clinical characteristics and a dismal prognosis. PATIENTS AND METHODS: We studied 834 consecutive MM patients in a single center in China and compared clinical features of patients with and without EMD. RESULTS: In general, the prevalence of EMD was 4.8% at the time of diagnosis and 3.4% during follow-up, with a significant increase in recent years. MM...
Source: Clinical Lymphoma and Myeloma - January 3, 2015 Category: Cancer & Oncology Authors: Deng S, Xu Y, An G, Sui W, Zou D, Zhao Y, Qi J, Li F, Hao M, Qiu L Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Characteristics of Sweet Syndrome in Patients With Acute Myeloid Leukemia.
CONCLUSION: SS occurs in 1% of AML patients; -5/del(5q) karyotype, FLT3 mutations, and AML with myelodysplasia-related features were more frequent among patients with SS. PMID: 25630528 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - December 24, 2014 Category: Cancer & Oncology Authors: Kazmi SM, Pemmaraju N, Patel KP, Cohen PR, Daver N, Tran KM, Ravandi F, Duvic M, Garcia-Manero G, Pierce S, Nazha A, Borthakur G, Kantarjian H, Cortes J Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Influence of Insurance and Marital Status on Outcomes of Adolescents and Young Adults With Acute Lymphoblastic Leukemia.
CONCLUSION: Insurance status and marriage did not influence outcomes for AYA with ALL, suggesting that intrinsic differences in disease and disease-specific therapies are more important than social issues. PMID: 25592548 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - December 12, 2014 Category: Cancer & Oncology Authors: Fintel AE, Jamy O, Martin MG Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Clinical Significance of Acquired Cytogenetic Clones in Patients With Treated Follicular Lymphoma.
CONCLUSION: Our results indicate that the presence of ACC alone is insufficient for diagnosis of tMNs. The proportion of cells with specific aberrations at first ACC, bone marrow dysplasia, and low platelet counts might predict outcome of ACC. PMID: 25573378 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - December 12, 2014 Category: Cancer & Oncology Authors: Wang XI, Yin CC, Qazilbash MH, Hu S, Lu G Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Analysis of B-Cell Subpopulations in Monoclonal Gammopathies.
cute; A, Kupská R, Penka M, Pour L, Adam Z, Hájek R Abstract BACKGROUND: Multiple myeloma (MM) is characterized by accumulation of pathological plasma cells (PCs) in bone marrow (BM) as a result of deregulation of B-cell development. To clarify its pathophysiology it is necessary to investigate in detail the developmental stages of B-cells. MATERIALS AND METHODS: Enumeration of total CD19-positive (CD19(+)) cells and their subpopulations together with PCs was done in peripheral blood (PB) and BM of newly diagnosed monoclonal gammopathy patients and control subjects. Representation of subsets was...
Source: Clinical Lymphoma and Myeloma - December 12, 2014 Category: Cancer & Oncology Authors: Všianská P, Říhová L, Varmužová T, Suská R, Kryukov F, Mikulášová A, Kupská R, Penka M, Pour L, Adam Z, Hájek R Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation.
CONCLUSION: Sorafenib appears to be an effective maintenance therapy after allo-HCT in FLT3-ITD AML, with achievement of durable complete responses. This suggests an immunomodulatory effect of sorafenib in the posttransplantation setting and warrants a broader clinical evaluation of the use of maintenance sorafenib in FLT3-ITD AML. PMID: 25550214 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - December 12, 2014 Category: Cancer & Oncology Authors: Antar A, Kharfan-Dabaja MA, Mahfouz R, Bazarbachi A Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Follicular lymphoma presenting with hypercalcaemia: an unusual mechanism of hypercalcaemia.
Abstract Hypercalcaemia is a frequent finding in patients with cancer. In up to 30% of malignancies, the disease course is complicated with hypercalcaemia. For hospitalized patients, cancer is the most common cause of hypercalcaemia. In normal physiological circumstances, the ionized calcium is kept in check by the influence of two important hormones, parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D (1,25(OH)2D). However, cancer can misbalance the calcium homeostasis by generating certain humoural mediators. Overproduction of parathyroid hormone-related peptide (PTH-rp), intact PTH, 1,25(OH)2D, and cytokines ...
Source: Clinical Lymphoma and Myeloma - December 4, 2014 Category: Cancer & Oncology Authors: Pieter M, Benyam A, Rajiv K Tags: Acta Clin Belg Source Type: research

Applying Janus Kinase 2 (JAK2) Inhibitors to the Treatment of Chronic Myelofibrosis.
PMID: 25439106 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - December 1, 2014 Category: Cancer & Oncology Authors: Verstovsek S, Levine RL, Stein BL Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Splenomegaly Secondary to Myeloproliferative Neoplasms and Portal Hypertension.
PMID: 25465464 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 6, 2014 Category: Cancer & Oncology Authors: Manenti A, Forghieri F, Colasanto D, MarioLuppi Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.
CONCLUSIONS: This analysis supports a switch from BSA-based to fixed dosing, without dose modification for mild/moderate renal impairment or age, in future adult studies of ixazomib, simplifying dosing guidance and clinical development. PMID: 25377318 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 6, 2014 Category: Cancer & Oncology Authors: Gupta N, Zhao Y, Hui AM, Esseltine DL, Venkatakrishnan K Tags: Br J Clin Pharmacol Source Type: research

Solitary extramedullary plasmocytoma of the thyroid: a case report and histological approach to plasma cells infiltrate in the thyroid gland.
Abstract Background: Solitary extramedullary plasmacytoma (SEP) is a rare malignant neoplasm arising from plasma cells. SEP mostly occurs in the upper respiratory tract. Thyroid gland is rarely affected (
Source: Clinical Lymphoma and Myeloma - November 2, 2014 Category: Cancer & Oncology Authors: Wilmars MM, Knoops L, Sempoux C, Galant C, Geets X, Poirel HA, Ameye G, Camboni A Tags: Acta Clin Belg Source Type: research

Clinical experience with plerixafor as a mobilization regimen for autologous peripheral blood stem cell transplantation in patients with refractory germ cell tumors.
eacute;s-Funés H Abstract The purpose of this study was to report our experience with administration of plerixafor for the mobilization of hematopoietic stem cells (HSCs) in patients with refractory or recurrent germ cell tumors who were candidates for salvage therapy with high-dose chemotherapy and HSC transplantation and for whom mobilization of HSCs had not been achieved by standard therapies. This retrospective and observational study selected patients who were eligible for autologous HSC transplantation (AHSCT) and received plerixafor after failure of HSC mobilization by granulocyte colony-stimulating ...
Source: Clinical Lymphoma and Myeloma - October 10, 2014 Category: Cancer & Oncology Authors: García-Escobar I, Parrilla L, Ortega LM, Castellanos D, Pallarés MA, Cortés-Funés H Tags: Mol Clin Oncol Source Type: research

Bortezomib-Contained Chemotherapy and Thalidomide Combined With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) Play Promising Roles in Plasmablastic Lymphoma: A Case Report and Literature Review.
PMID: 25225082 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 19, 2014 Category: Cancer & Oncology Authors: Cao C, Liu T, Zhu H, Wang L, Kai S, Xiang B Tags: Clin Lymphoma Myeloma Leuk Source Type: research